Enterome raises $19 million to fund clinical development of OncoMimics™ immunotherapy to treat Follicular Lymphoma
“Attracting highly specialized blood cancer investor IFLI to this financing demonstrates the conviction of our new and existing investors in the potential of OncoMimics™ for blood and solid tumor cancers,” said Pierre Bélichard, Enterome’s Chief Executive Officer. “We currently are generating exciting clinical proof of concept data for EO2463 monotherapy in several iNHL patient populations included in the Phase 1/2 SIDNEY clinical trial. Most importantly, EO2463 has shown robust clinical efficacy and exceptional safety and tolerability – which is especially impressive for such a potent immunotherapy. This offers a new hope for these patients and a rare opportunity to create an entirely new market segment for an impactful therapeutic. This financing will enable us to continue the SIDNEY trial of EO2463 and prepare to launch a first pivotal Phase 3 trial of this candidate for the ‘watch-and-wait’ iNHL population.”
Share:
More News
Taiho Oncology, Inc. completed a New Drug Application (NDA) submission to the U.S. Food and Drug Administration (FDA) for zipalertinib in combination with platinum-based chemotherapy for the treatment of patients with previously untreated, locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) exon 20
“This collaboration reflects our conviction that atebimetinib has the potential to become an essential backbone therapy in a broad range of combinations across MAPK-driven cancers,” said Ben Zeskind, Immuneering CEO and co-founder. “Atebimetinib’s unique tolerability profile and broad activity make it well suited to combine with a wide range of
“These final updated results provide continued evidence of the potential for γδ T cell therapies to drive activity and improve outcomes for patients,” said William Ho, CEO and co-founder of IN8bio. “The clinical outcomes and observed activity are supported by our correlative analysis, including histopathology, demonstrating the expansion and persistence
“Patients with RAS-mutated mCRC have no first-line therapies specifically approved for their disease, and Fast Track designation reflects the potential of onvansertib to address this serious unmet need,” said Mani Mohindru, PhD, President and Chief Executive Officer of Cardiff Oncology. “Our randomized Phase 2 data give us confidence that onvansertib